|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||145,100 g/mol (for the peptide) g·mol−1|
|(what is this?)|
Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma and hematological malignancies.
This drug was developed by Seattle Genetics, Inc.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
- Advani, R.; Forero-Torres, A.; Furman, R. R.; Rosenblatt, J. D.; Younes, A.; Ren, H.; Harrop, K.; Whiting, N.; Drachman, J. G. (2009). "Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma". Journal of Clinical Oncology. 27 (26): 4371–4377. doi:10.1200/JCO.2008.21.3017. PMID 19636010.
- Khubchandani; Czuczman, M. S.; Hernandez-Ilizaliturri, F. J. (2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current Opinion in Investigational Drugs. 10 (6): 579–587. PMID 19513947.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|